The JAK2 V617F mutation is characteristic of most Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and occurs rarely in de novo acute myeloid leukaemia (AML). We sought to characterize AMLs that harbour this mutation and distinguish those that arise de novo (AML-DN) from those that reflect transformation of an underlying MPN (AML-MPN). Forty-five patients with JAK2 V617F-mutated AML were identified; 15 were AML-DN and 30 were AML-MPN. AML-MPN cases were more likely to have splenomegaly (P = 0Á02), MPN-like megakaryocytes and higher mean JAK2 V617F VAF at diagnosis (P = 0Á04). Mutations involving TET2 were exclusively identified in AML-DN patients. Mutations of genes affecting DNA methylation were more common in AML-DN (P < 0Á01). A complex karyotype was more frequent in AML-MPN cases than in AML-DN (P < 0Á01), with AML-DN more likely to display a normal karyotype (P = 0Á02). Bone marrow histology after recovery from induction chemotherapy in AML-DN cases revealed no morphological evidence of any previously occult MPNs, while this was evident in most of the AML-MPN specimens (P < 0Á01). These findings in this largest study of JAK2 V617F-mutated AMLs indicate that AML-DN is distinct from AML-MPN.
The JAK2 V617F mutation was first described over a decade ago and results in a valine-to-phenylalanine substitution at codon 617 of the JAK2 protein. This mutation results in constitutive kinase activity and is characteristic of the majority of Philadelphia chromosome-negative MPNs. The prevalence of this mutation varies among different MPNs; approximately half of the cases of essential thrombocythaemia (ET) and primary myelofibrosis (PMF) carry the mutation while the vast majority (~95%) of polycythaemia vera (PV) cases are positive for JAK2 V617F (Swerdlow et al, 2008) . This mutation is also frequently detected in AML that follows a prior diagnosis of an MPN (i.e. blast phase of MPN), although, of note, some JAK2-positive MPNs progress to JAK2-negative AMLs (Theocharides et al, 2007) . The JAK2 mutation also occurs very rarely (incidence of approximately 1%) in apparently de novo AML without an antecedent MPN (Levine et al, 2005; Lee et al, 2006; Illmer et al, 2007) . One group has demonstrated that AML cases with inv(16)/t (16;16) or t(8;21) that have the JAK2 V617F mutation have a more aggressive clinical course and are associated with more frequent secondary karyotypic abnormalities when compared with those that are negative for the mutation (Illmer et al, 2007) .
In the current era of next-generation sequencing (NGS), the prognostic and therapeutic impact of somatic mutations in AML is becoming increasingly relevant as more detailed information about mutations is becoming gradually more available in the clinical setting. In particular, the mutational status of JAK2 is of clinical consequence as targeted therapies are already in use in standard medical practice for the management of patients with PMF (Hobbs et al, 2017) . The purpose of this multi-institutional, retrospective study was to characterize JAK2 V617F-mutated AML and to compare cases that apparently arise de novo (AML-DN) with those that reflect transformation of an underlying MPN (AML-MPN).
Materials and methods
Following Institutional Review Board-approval in each institution, 45 AML patients were identified as having a JAK2 V617F mutation by NGS or allele specific polymerase chain reaction over a 5-year period (November 2011 to October 2016 Swerdlow et al, 2017) , presence or absence of splenomegaly, peripheral blood counts, bone marrow biopsy morphological characteristics (specifically megakaryocyte morphology both before and after any AMLdirected therapy), JAK2 mutation VAF (both before and after induction therapy), presence of other mutations (both before and after induction therapy), cytogenetics, AML therapy, MPN therapy, and clinical outcome were obtained from the electronic medical record. Megakaryocyte morphology was evaluated and scored as being either MPN-like (large, hyperlobated or staghorn nuclei, bulbous nuclei, clustering) or non-MPN-like (either normal or myelodysplastic-like, with the latter being small, with hypolobated nuclei, or separated nuclear lobes). The European consensus system was used to grade fibrosis (Thiele et al, 2005) .
Conventional cytogenetic analyses were performed on G-banded metaphases prepared from marrow aspirates using standard techniques. When possible, 20 metaphases were analysed and the result was reported using the International System for Human Cytogenetic Nomenclature (McGowanJordan et al, 2016) . DNA was prepared from the submitted bone marrow or peripheral blood specimens by standard methods, specific to each institution. Although the NGS methodologies and specific genes assessed varied between institutions, all panels utilized amplicon-based library preparation methodologies and were sequenced with the Illumina Tables I and II , respectively, while a comparison of the major features in these two groups is summarised in Table III . A number of statistically significant differences between the two groups were noted. Splenomegaly was seen more commonly in AML-MPN patients (53%) than in AML-DN cases (20%) at the time of AML diagnosis (P = 0Á02). There were no differences in haematological parameters. MPN-like megakaryocytic atypia was more common in AML-MPN cases (70%) when compared to AML-DN (13%) (P < 0Á01) among cases in which the diagnostic AML bone marrow specimens were available for analysis (Fig 1A, B) . Morphological review of bone marrow specimens collected after recovery from induction chemotherapy (available for 10/15 AML-DN and 17/30 AML-MPN patients) was performed to evaluate for the presence or absence of morphological features suggestive of an underlying MPN (i.e. MPN-like megakaryocytes). In the AML-DN cohort, there was no histological evidence of MPN-like morphology in any of the post-treatment marrows examined ( Fig 1C) while 76% of AML-MPN cases demonstrated morphological evidence of their previously diagnosed MPN ( Fig 1D) Data acquired at time of AML diagnosis except for peak platelet count, post-therapy marrow fibrosis and megakaryocytic morphology. Marrow fibrosis graded using the European consensus system.
-, data not available or insufficient material to assess; AML, acute myeloid leukaemia; AML-DN, de novo acute myeloid leukaemia; BM, bone marrow; F, female; Hb, haemoglobin; M, male; M1, myeloblastic without maturation; M2, myeloblastic with maturation; M4, myelomonoblastic; MPN, myeloproliferative neoplasm; MRC, myelodysplasia-related changes; NOS, not otherwise specified, with morphological subtype noted if reported; PB, peripheral blood; PLT, platelet count; RCA, recurrent cytogenetic abnormalities; TRMN, therapy-related myeloid neoplasm; WBC, white blood cell count. *This AML also demonstrated t(8;21) and received chemotherapy for breast cancer 3 years prior to diagnosis of AML. Data acquired at time of AML diagnosis except for peak platelet count, post-therapy marrow fibrosis and megakaryocytic morphology. Marrow fibrosis graded using the European consensus system.
-, data not available or insufficient material to assess; AML-MPN, Acute myeloid leukaemia reflecting transformation of an underlying myeloproliferative neoplasm; BM, bone marrow; ET, essential thrombocythaemia F, female; Hb, haemoglobin; M, male; M0, minimally differentiated; M1, myeloblastic without maturation; M2, myeloblastic with maturation; M4, myelomonoblastic; M7, megakaryoblastic; MPAL, mixed phenotype acute leukaemia; MPN, myeloproliferative neoplasm; MRC, myelodysplasia-related changes; NOS, not otherwise specified, with morphological subtype noted if reported; PB, peripheral blood; PETMF, post-ET myelofibrosis; PLT, platelet count; PMF, primary myelofibrosis; PV, polycythaemia vera; TRMN, therapy-related myeloid neoplasm; WBC, white blood cell count. *This diagnosis of TRMN is based upon the administration of known leukaemogenic therapy (cyclophosphamide, docetaxel and radiation) for invasive breast cancer.
JAK2 V617F-Positive Acute Myeloid Leukaemia ª 2018 John Wiley & Sons Ltd
of AML diagnosis and also when examined following induction therapy (mean MF grades 2Á1 and 1Á4, respectively), these differences were not statistically significant. Cytogenetic and molecular genetic findings in the 45 cases are detailed in Fig 2, with the major features compared in Table III . A complex karyotype (i.e. ≥3 abnormalities) was found more frequently in the AML-MPN cohort (57%) versus AML-DN (13%) (P < 0Á01) whereas a normal karyotype was detected in 47% of AML-DN patients but only in 13% of the AML-MPN patients (P = 0Á02). AML-MPN patients had a higher mean JAK2 V617F VAF at the time of AML diagnosis when compared to the AML-DN cases (50% vs. 32%, respectively, P = 0Á04). In addition to the JAK2 V617F, additional mutations involving TET2 (n = 3, P = 0Á03) were exclusively identified in AML-DN patients. Other single genes were exclusively mutated in the different groups but these did not reach statistical significance. Mutations in genes involved in DNA methylation were significantly more common in AML-DN compared to AML-MPN (20% and 6Á6%, P < 0Á01). Most of the patients in the AML-MPN cohort received therapy for their MPN prior to the development of AML. Of these, 18 were treated with hydroxycarbamide, 3 with aspirin, 3 with phlebotomy, 2 with ruxolitinib, 2 with decitabine, 2 with anagrelide, 2 with interferon and 1 with thalidomide.
AML-MPN patients demonstrated worse overall survival with a median survival of 6 months, than AML-DN cases (median survival of 8 months); however, this was not statistically significant (P = 0Á08, Fig 3) . By contrast, the proportion of patients alive at the end of the study period was significantly higher in the AML-DN group as compared to AML-MPN group (60% vs. 27%, P = 0Á05).
Discussion
In this largest-to-date study of AML with JAK2 V617F mutation, we found that AML-MPN is a genetically distinct and clinically more aggressive disease than AML-DN although the follow-up period in this study (mean: 10 months) was relatively short. This work supports the notion that AML-DN is, in fact, a different biological entity from AML-MPN, with the additional implication that the JAK2 V617F mutation, when detected in apparent cases of de novo AML-DN, is not necessarily evidence of an underlying transformation of an occult MPN. The cytogenetic profiles of AML-DN and AML-MPN were distinct, as were their mutational profiles when AML, acute myeloid leukaemia; AML-DN, de novo acute myeloid leukaemia; AML-MPN, acute myeloid leukaemia reflecting transformation of an underlying myeloproliferative neoplasm; MPN, myeloproliferative neoplasm; PB, peripheral blood; WBC, white blood cell count.
-denotes P > 0Á05.
studied by NGS. The heightened frequency of complex karyotypes seen within the AML-MPN cohort is not explained by prior therapy, as none of the patients received leukaemogenic agents in the treatment of their MPNs. It is worth noting that 18 of 30 patients received hydroxycarbamide; although there has been some historic concern regarding this agent's leukaemogenicity, a recent large study revealed that it is not associated with a significantly increased risk of MPN transformation (Bj€ orkholm et al, 2011) . It is interesting that, in the present study, TET2 mutations were only observed in AML-DN (3 of 15 cases) and not at all in AML-MPN, because this mutation is known to occur in patients with MPNs in general and has been associated with JAK2 V617F in particular (Delhommeau et al, 2009 ). The relative frequency (40%) of a background of ET (which is the least likely Philadelphia chromosome-negative MPN to progress to blast phase) in the AML-MPN group is also of uncertain significance, but may be due to cases with early PMF being misdiagnosed as ET or simply due to small sample size. Unfortunately, many of the originally diagnosed MPN biopsies, obtained prior to blast transformation, were not available for review. While JAK2 V617F has a well-defined role as a driver mutation in MPNs (Rumi et al, 2014) , its role as a potential driver mutation in AML-DN is less clear, given the infrequency of the mutation in this setting (Papaemmanuil et al, 2016) . However, none of the AML-DN patients exhibited morphological evidence of an MPN in their post-induction recovery marrows when these data were available and, conversely, megakaryocytic atypia was commonly seen in AML-MPN marrows at the time of AML diagnosis when compared to AML-DN. A recent study evaluated AMLs with JAK2 V617F (equivalent to AML-DN in our study). In contrast to our approach, this study compared AML-DN with AMLs that were wild-type for JAK2 (Hidalgo-L opez et al, 2017).
Their study noted more frequent complex karyotypes in AML-DN (27%) compared to our data (13%) as well as a different pattern of mutations. The reasons for this discordance are unclear but may be related to the low numbers of AML-DN cases in both studies. Mutations in TET2, NPM1, LUC72L, STAG2, NOTCH1, SMC1A, HNRNPK and CEBPA were exclusively identified in AML-DN patients. Abnormalities of ETV6, NRAS, BCOR, SF3B1, CBL, GATA2, RAD21, KRAS, ABL1 and PTPN11 were found only in the AML-MPN cohort, whereas mutations in ATM, IDH1, IDH2, RUNX1, ASXL2, DNMT3A, SRSF2, FLT3, U2AF1, PHF6, CBL, EZH2 and TP53 were seen in both AML-DN and AML-MPN categories (Fig 2) . TP53 mutations have been previously shown to be associated with complex cytogenetic aberrations (R€ ucker et al, 2012) . In our study, seven of the eight patients with TP53 mutations also had complex karyotypes, which is in keeping with these observations.
In conclusion, the findings in this study of AML with JAK2 V617F mutation support the hypothesis that those arising de novo represent a biological entity distinct from those that represent blast phase of prior MPN. Compared to the latter, de novo AML with JAK2 V617F mutation has lower VAF, fewer complex karyotypes, more frequent mutations in 
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